OmniAb, Inc.
OABIBiotechnology
$5.23−0.95%As of Oct 29vs prior close
- Market cap
- $760.4M
- P/E (TTM)
- –
- From 52W high
- −0.95%
- EPS (LTM)
- -$0.34
- Revenue (LTM)
- $40.2M
- Net margin
- -115.12%
Nomior Score
61
Steady ProfileTop 25% of the scored universe
Growth61
Quality51
Value52
Momentum86
Resilience34
Growth
−14.39%revenue a year over 4 fiscal years
YE21 $34.7MLTM $40.2M
Connections
Revenue to profitQ3 FY26
The operating loss was 410% of revenue, narrower by 400 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $4.0 million
- Net loss
- $15.7 million
- Revenue outlook
- $35 million to $39 million
Third quarter revenue rose from the prior-year period, driven mainly by service revenue and xPloration revenue. The company still reported a net loss for the quarter, which was smaller than the loss a year earlier. The company raised its full-year revenue and cash outlook.
Who owns it
2funds